Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
Abstract Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients to the treatment most likely to be of benefit. Existing gene expression profiling (GEP)-based...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e97b11a5b0b44e6cb64f859733a26b77 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e97b11a5b0b44e6cb64f859733a26b77 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e97b11a5b0b44e6cb64f859733a26b772021-12-02T14:06:13ZRatio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma10.1038/s41525-021-00169-w2056-7944https://doaj.org/article/e97b11a5b0b44e6cb64f859733a26b772021-02-01T00:00:00Zhttps://doi.org/10.1038/s41525-021-00169-whttps://doaj.org/toc/2056-7944Abstract Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients to the treatment most likely to be of benefit. Existing gene expression profiling (GEP)-based biomarkers for ICI are primarily focused on measuring a T cell-inflamed tumor microenvironment that contributes positively to the response to ICI. Here, we identified an immunosuppression signature (IMS) through analyzing RNA sequencing data from a combined discovery cohort (n = 120) consisting of three publicly available melanoma datasets. Using the ratio of an established IFN-γ signature and IMS led to consistently better prediction of the ICI therapy outcome compared to a collection of nine published GEP signatures from the literature on a newly generated internal validation cohort (n = 55) and three published datasets of metastatic melanoma treated with anti-PD-1 (n = 54) and anti-CTLA-4 (n = 42), as well as in patients with gastric cancer treated with anti-PD-1 (n = 45), demonstrating the potential utility of IMS as a predictive biomarker that complements existing GEP signatures for immunotherapy.Chuanliang CuiCanqiang XuWenxian YangZhihong ChiXinan ShengLu SiYihong XieJinyu YuShun WangRongshan YuJun GuoYan KongNature PortfolioarticleMedicineRGeneticsQH426-470ENnpj Genomic Medicine, Vol 6, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Genetics QH426-470 |
| spellingShingle |
Medicine R Genetics QH426-470 Chuanliang Cui Canqiang Xu Wenxian Yang Zhihong Chi Xinan Sheng Lu Si Yihong Xie Jinyu Yu Shun Wang Rongshan Yu Jun Guo Yan Kong Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| description |
Abstract Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients to the treatment most likely to be of benefit. Existing gene expression profiling (GEP)-based biomarkers for ICI are primarily focused on measuring a T cell-inflamed tumor microenvironment that contributes positively to the response to ICI. Here, we identified an immunosuppression signature (IMS) through analyzing RNA sequencing data from a combined discovery cohort (n = 120) consisting of three publicly available melanoma datasets. Using the ratio of an established IFN-γ signature and IMS led to consistently better prediction of the ICI therapy outcome compared to a collection of nine published GEP signatures from the literature on a newly generated internal validation cohort (n = 55) and three published datasets of metastatic melanoma treated with anti-PD-1 (n = 54) and anti-CTLA-4 (n = 42), as well as in patients with gastric cancer treated with anti-PD-1 (n = 45), demonstrating the potential utility of IMS as a predictive biomarker that complements existing GEP signatures for immunotherapy. |
| format |
article |
| author |
Chuanliang Cui Canqiang Xu Wenxian Yang Zhihong Chi Xinan Sheng Lu Si Yihong Xie Jinyu Yu Shun Wang Rongshan Yu Jun Guo Yan Kong |
| author_facet |
Chuanliang Cui Canqiang Xu Wenxian Yang Zhihong Chi Xinan Sheng Lu Si Yihong Xie Jinyu Yu Shun Wang Rongshan Yu Jun Guo Yan Kong |
| author_sort |
Chuanliang Cui |
| title |
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| title_short |
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| title_full |
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| title_fullStr |
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| title_full_unstemmed |
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma |
| title_sort |
ratio of the interferon-γ signature to the immunosuppression signature predicts anti-pd-1 therapy response in melanoma |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/e97b11a5b0b44e6cb64f859733a26b77 |
| work_keys_str_mv |
AT chuanliangcui ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT canqiangxu ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT wenxianyang ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT zhihongchi ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT xinansheng ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT lusi ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT yihongxie ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT jinyuyu ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT shunwang ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT rongshanyu ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT junguo ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma AT yankong ratiooftheinterferongsignaturetotheimmunosuppressionsignaturepredictsantipd1therapyresponseinmelanoma |
| _version_ |
1718392056793006080 |